SGLT2 Inhibitors and Wound Care: A Practitioner's Protocol

If you're treating diabetic foot ulcer patients in 2026, a significant portion of them are on SGLT2 inhibitors. Empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) are now first-line agents for type 2 diabetes with cardiovascular or renal comorbidity — which describes most of your complex wound care patients. Understanding how SGLT2 inhibitors interact with wound healing, and what risks to watch for, is becoming a core clinical competency for any wound care practitioner.

These drugs intersect your practice at several critical points: elevated lower extremity amputation risk, the rare but serious risk of Fournier's gangrene, and the potential for euglycemic diabetic ketoacidosis (DKA) around procedures. This guide covers what you need to know clinically, how to document it, and when to escalate.

How SGLT2 Inhibitors Affect Wound Healing

SGLT2 (sodium-glucose cotransporter-2) inhibitors block glucose reabsorption in the proximal tubule, causing glucose excretion in the urine. This lowers blood glucose and reduces cardiovascular events — but at the wound site, the picture is more nuanced.

The increased urinary glycosuria creates a more permissive environment for local bacterial proliferation, particularly around periwound skin, digit web spaces, and perineal areas. For patients with existing peripheral neuropathy or vascular compromise — your typical complex wound patient — this altered local environment can slow healing and increase the risk of secondary infection.

The osmotic diuresis caused by SGLT2 inhibitors can also contribute to dehydration and relative hemoconcentration. In poorly perfused limbs, this can further impair oxygen delivery to already ischemic wound tissue, compounding the existing arterial deficit.

Lower Extremity Amputation Risk: What Practitioners Need to Know

The FDA added a black box warning to canagliflozin in 2017 following findings from the CANVAS program, which observed approximately twice the rate of lower extremity amputations compared to placebo. The signal has been less consistent for empagliflozin and dapagliflozin in subsequent trials, but all SGLT2 inhibitors carry regulatory language about monitoring lower extremity status.

For your practice, the clinical takeaway is direct: when a patient on any SGLT2 inhibitor presents with a new diabetic foot ulcer or worsening lower extremity wound, the medication belongs in the clinical picture. Document whether the prescribing provider is aware of the wound and has reviewed continued SGLT2 use in the context of the patient's current presentation. This contemporaneous documentation can be critical if the wound deteriorates.

The risk for serious outcomes appears highest in patients who also have:

• Prior lower extremity amputation or partial foot amputation
• Peripheral vascular disease with ABI below 0.6
• Active foot infection or Wagner Grade 3 or higher ulceration
• Peripheral neuropathy with reduced protective sensation

ABI Assessment in SGLT2-Exposed Patients

Before initiating aggressive wound intervention in a patient on SGLT2 inhibitor therapy, complete vascular assessment belongs in your initial evaluation. Ankle-brachial index (ABI) testing should be part of your standard new DFU workflow regardless of medication history — but the threshold for vascular surgery referral warrants careful consideration when a gliflozin is part of the medication list.

Document ABI values and correlate them with clinical perfusion findings. An ABI below 0.5 or a non-compressible result (ABI above 1.3) in a patient on canagliflozin warrants urgent vascular surgery consultation before you proceed with sharp debridement or skin substitute application. Your chart needs to show that perfusion adequacy was assessed before intervention.

For a detailed framework on lower extremity vascular assessment in wound care, see our guide on peripheral artery disease evaluation and documentation.

Fournier's Gangrene: Recognition and Your Responsibility

Fournier's gangrene — necrotizing fasciitis of the perineum and external genitalia — was added as an FDA warning for the entire SGLT2 inhibitor class in 2018. While the absolute incidence remains low, wound care practitioners are positioned to recognize it earlier than almost any other provider, because you're looking at skin and soft tissue every day.

The early presentation: severe pain or tenderness in the perineal area, often out of proportion to visible findings. Crepitus, rapidly spreading erythema, and constitutional symptoms follow. Any patient on an SGLT2 inhibitor who describes unusual genital or perineal discomfort during your visit deserves same-day evaluation, not a "monitor it" recommendation.

If you identify a suspected case:

• Discontinue the SGLT2 inhibitor and notify the prescribing provider immediately
• Same-day surgical consultation — this is not a wound you manage outpatient
• ICD-10 coding: N49.3 for male patients (Fournier's disease), N76.89 for female patients (other specified inflammatory diseases of vagina and vulva, which codes Fournier's in female patients)

Document the timeline, your clinical assessment, referral, and all communication clearly. These cases generate medicolegal scrutiny. Your chart needs to show recognition was timely and escalation was appropriate.

Perioperative Management: Euglycemic DKA

If your patient on an SGLT2 inhibitor is heading toward a surgical debridement, skin substitute application, or any procedure requiring anesthesia, coordinate with their endocrinologist or primary prescriber about holding the medication in advance.

Euglycemic DKA — diabetic ketoacidosis with near-normal blood glucose — is a recognized SGLT2 inhibitor complication in the perioperative setting. It can be missed because glucose levels do not trigger standard clinical suspicion. Most anesthesia protocols now recommend holding SGLT2 inhibitors 3 to 4 days before elective procedures, with patients maintaining adequate hydration and carbohydrate intake during the hold period.

Document this coordination explicitly in your chart. A brief note — "Patient's endocrinologist notified of planned sharp debridement. Empagliflozin to be held per their protocol starting [date]" — establishes appropriate co-management and protects your practice if perioperative complications arise. Co-management documentation also supports higher E/M code selection when it's clearly recorded.

Wound Management Protocol Adjustments

Clinical management of wounds in SGLT2 inhibitor patients follows the same evidence-based framework as all DFU care — with heightened attention to infection surveillance and perfusion status. See our complete diabetic foot ulcer guide for the full protocol.

Key adjustments for SGLT2-exposed patients:

Offloading: Start more aggressively. A patient with impaired perfusion and documented amputation risk cannot afford suboptimal pressure relief. Review your offloading strategies and default toward total contact casting or irremovable devices in patients with significant vascular compromise.

Infection surveillance: Shorten reassessment intervals. SGLT2-related glycosuria creates a local wound environment that can mask early infection markers. Probe-to-bone testing and lower MRI threshold for osteomyelitis suspicion are warranted in this population. Our wound infection assessment guide covers the clinical decision points.

Prescriber communication cadence: Flag these patients for closer loop-back intervals with their endocrinologist or primary provider. The wound outcome and medication management decision belong together. Your documentation of this communication supports complex care coordination and provides a clear audit trail.

For comparison with the GLP-1 drug class — also common in your DFU patient population — see our post on GLP-1 agonists and wound healing. GLP-1 receptor agonists carry different risk profiles and interact with wound physiology through distinct mechanisms.

Key Takeaways

• Canagliflozin carries an FDA black box warning for lower extremity amputation risk; all SGLT2 inhibitors carry a class warning for Fournier's gangrene. Document SGLT2 inhibitor status at every new DFU evaluation.
• ABI assessment before aggressive wound intervention is essential in SGLT2-exposed patients; the threshold for vascular surgery referral should be applied conservatively.
• Fournier's gangrene presents with perineal pain often disproportionate to visible findings — recognize it early and escalate the same day. Code N49.3 (male) or N76.89 (female).
• Coordinate SGLT2 inhibitor hold with the prescribing provider 3 to 4 days before any planned procedure to reduce euglycemic DKA risk. Document this coordination explicitly.
• More aggressive offloading, shorter reassessment intervals, and lower infection thresholds can help offset the adverse wound healing environment associated with SGLT2 inhibitor use.
• Co-management documentation across prescribers supports appropriate E/M code selection and protects your practice in audit scenarios.